Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma

  • Jong-kyu Kim
  • Chan Yong Seong
  • In Eui Bae
  • Jin Wook Yi
  • Hyeong Won Yu
  • Su-jin Kim
  • Jae-Kyung Won
  • Young Jun Chai
  • June Young Choi
  • Kyu Eun Lee
Endocrine Tumors

Abstract

Background

BRAFV600E mutation is the most common somatic variant in papillary thyroid carcinoma (PTC) and is associated with aggressive prognostic factors. The conventional detection method for BRAF mutations is polymerase chain reaction followed by Sanger sequencing. Recently, an immunohistochemistry (IHC) method using a BRAFV600E-specific antibody (VE1) has been developed and widely adopted in the clinics; however, there is a lack of evidence regarding the comparability of the IHC and Sanger sequencing methods.

Methods

Our institution began using the BRAFV600E IHC test in January 2013. We retrospectively analyzed 697 samples that were tested using both the IHC and sequencing methods, and evaluated their concordance.

Results

BRAF mutation was detected in 90.0% (627/697) of samples using IHC and 83.4% (581/697) of samples using direct sequencing. The diagnostic parameters of IHC compared with Sanger sequencing were as follows: 100% sensitivity (581/581), 60.3% specificity (70/116), 92.7% positive predictive value (581/627), and 100% negative predictive value (70/70). No false negative results were recorded using IHC. The overall concordance rate between the two methods was 93.4% (651/697). Discordant results were found in 46 samples (6.6%), 29 of which were from cases with small tumors (< 6 mm), 8 were from cases with low tumor cellularity, and 9 were specimens yielding low-quality DNA.

Conclusions

IHC using the VE1 antibody is a reliable and highly sensitive method for detecting the BRAFV600E mutation in classic PTC.

Notes

Disclosures

Jong-kyu Kim, Chan Yong Seong, In Eui Bae, Jin Wook Yi, Hyeong Won Yu, Su-jin Kim, Jae-Kyung Won, Young Jun Chai, June Young Choi, and Kyu Eun Lee declare no conflicts of interest.

References

  1. 1.
    Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015;262:519–25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010;200:136–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Ihle MA, Fassunke J, Konig K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14:13.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kim BH, Kim IJ, Lee BJ, et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med J. 2015;56:634–40.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zagzag J, Pollack A, Dultz L, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery. 2013;154:1199–204.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wobker SE, Kim LT, Hackman TG, Dodd LG. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma. Cancer Cytopathol. 2015;123:531–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhu X, Luo Y, Bai Q, et al. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Exp Mol Pathol. 2016;100:236–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Boursault L, Haddad V, Vergier B, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS ONE 2013;8:e70826.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin N Am. 2009;23:529–45.CrossRefPubMedGoogle Scholar
  16. 16.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;27:949–54.CrossRefGoogle Scholar
  17. 17.
    Mathur A, Moses W, Rahbari R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer. 2011;117:4390–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jung CK, Im SY, Kang YJ, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22:791–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee SE, Hwang TS, Choi YL, et al. BRAF Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAFV600E mutation. Thyroid. 2017;27:802–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Menzies AM, Lum T, Wilmott JS, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol. 2014;38:377–82.CrossRefPubMedGoogle Scholar
  21. 21.
    Walts AE, Pao A, Sacks W, Bose S. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. Hum Pathol. 2014;45:935–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15:94–100.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhang H, Zheng X, Ji T, et al. Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras Kit and Sanger DNA sequencing. Cell Biochem Biophys. 2012;62:415–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;23:1058–69.CrossRefGoogle Scholar
  26. 26.
    McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci USA. 2014;111:1600–9.CrossRefGoogle Scholar
  27. 27.
    Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718–26.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118:1764–73.CrossRefPubMedGoogle Scholar
  29. 29.
    Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine. 2012;91:274–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Xing M. BRAF mutation in papillary thyroid cancer: pathologenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jong-kyu Kim
    • 1
  • Chan Yong Seong
    • 2
  • In Eui Bae
    • 3
  • Jin Wook Yi
    • 2
  • Hyeong Won Yu
    • 3
  • Su-jin Kim
    • 2
  • Jae-Kyung Won
    • 4
  • Young Jun Chai
    • 5
  • June Young Choi
    • 3
  • Kyu Eun Lee
    • 2
  1. 1.Department of General SurgeryEwha Womans University College of Medicine and Graduate School of MedicineSeoulKorea
  2. 2.Department of SurgerySeoul National University Hospital and College of MedicineSeoulKorea
  3. 3.Department of Surgery, Seoul National University College of MedicineSeoul National University Bundang HospitalSeongnamKorea
  4. 4.Department of PathologySeoul National University Hospital and College of MedicineSeoulKorea
  5. 5.Department of SurgerySeoul National University Boramae Medical CenterSeoulKorea

Personalised recommendations